eli lilly glp-1 supply news today continues to expand its empire of factories with new $3B buildout Amid GLP-1 supply constraints, Lilly

In summary, there remains a lack of clinically relevant data on rhein and emodin, thereby necessitating further exploration into its clinical efficacy as well as appropriate dosing and treatment regimens

Read more about these FDA concerns here

Holistic Approach to Wellness It's also worth considering how MIC B12 injections fit into a bigger picture

PMC 3328495

Abdominal obesity, also known as visceral obesity, is one of the most difficult types of overweight to combat

However, starting with an SGLT2 inhibitor or a GLP-1 RA in an individual who is intolerant to metformin (primarily diarrhea) is a good choice, and even in the future we may see large diabetes organizations recommending these two classes as first line therapy once they get less expensive.